AR037148A1 - Sal sodica cristalina,procedimiento para su preparacion y su uso para la preparacion de un medicamento. - Google Patents

Sal sodica cristalina,procedimiento para su preparacion y su uso para la preparacion de un medicamento.

Info

Publication number
AR037148A1
AR037148A1 ARP020104113A ARP020104113A AR037148A1 AR 037148 A1 AR037148 A1 AR 037148A1 AR P020104113 A ARP020104113 A AR P020104113A AR P020104113 A ARP020104113 A AR P020104113A AR 037148 A1 AR037148 A1 AR 037148A1
Authority
AR
Argentina
Prior art keywords
preparation
procedure
sodium salt
crystalline sodium
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP020104113A
Other languages
English (en)
Inventor
Donsbach Kai Dr
Irmgard Hof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR037148(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR037148A1 publication Critical patent/AR037148A1/es
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una sal sódica cristalina del ácido 4'-[2-n-propil-4-metil-6-(1-metilbencimidazol-2-il)bencimidazol-1-il-metil]bifenil-2-carboxílico (INN: Telmisartan), a un procedimiento para su preparación, así como a su uso para la preparación de un medicamento.
ARP020104113A 2001-10-31 2002-10-30 Sal sodica cristalina,procedimiento para su preparacion y su uso para la preparacion de un medicamento. Pending AR037148A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels

Publications (1)

Publication Number Publication Date
AR037148A1 true AR037148A1 (es) 2004-10-27

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104113A Pending AR037148A1 (es) 2001-10-31 2002-10-30 Sal sodica cristalina,procedimiento para su preparacion y su uso para la preparacion de un medicamento.

Country Status (35)

Country Link
EP (1) EP1442023B1 (es)
JP (1) JP5124076B2 (es)
KR (1) KR100929502B1 (es)
CN (1) CN100509789C (es)
AR (1) AR037148A1 (es)
AT (1) ATE370125T1 (es)
AU (1) AU2002338886B2 (es)
BR (1) BR0213568A (es)
CA (1) CA2463146C (es)
CO (1) CO5580785A2 (es)
CY (1) CY1107504T1 (es)
DE (2) DE10153737A1 (es)
DK (1) DK1442023T3 (es)
EA (1) EA007596B1 (es)
EC (1) ECSP045089A (es)
ES (1) ES2291505T3 (es)
HK (1) HK1073841A1 (es)
HR (1) HRPK20040372B3 (es)
HU (1) HUP0402391A3 (es)
IL (2) IL161165A0 (es)
ME (1) MEP43608A (es)
MX (1) MXPA04004013A (es)
MY (1) MY129741A (es)
NO (1) NO326465B1 (es)
NZ (1) NZ532716A (es)
PE (1) PE20030629A1 (es)
PL (1) PL211462B1 (es)
PT (1) PT1442023E (es)
RS (1) RS50879B (es)
SA (1) SA02230419B1 (es)
SI (1) SI1442023T1 (es)
TW (2) TWI341200B (es)
UA (1) UA82833C2 (es)
UY (1) UY27520A1 (es)
WO (1) WO2003037876A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
KR100908308B1 (ko) * 2004-05-05 2009-07-17 테바 파마슈티컬 인더스트리즈 리미티드 순도가 높은 칸데사르탄 실렉세틸의 제조
EP1805146A4 (en) 2004-10-18 2009-01-14 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF TELMISARTAN
KR20070072588A (ko) * 2004-11-03 2007-07-04 테바 파마슈티컬 인더스트리즈 리미티드 텔미사르탄 나트륨의 비정질형 및 다형
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2012055941A1 (en) 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
US9561610B2 (en) * 2011-06-24 2017-02-07 Honda Motor Co., Ltd. Injection molding method and apparatus therefor
PL3421470T3 (pl) 2011-11-25 2021-08-02 Adverio Pharma Gmbh Podstawione 5-fluoro-1H-pirazolopirydyny w postaci krystalicznej
DK3209647T3 (da) 2014-10-21 2020-08-24 Ariad Pharma Inc Krystallinske former af 5-chlor-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidin-2,4-diamin
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
KR20200026975A (ko) 2017-07-07 2020-03-11 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
JP2022517610A (ja) * 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド 複素環化合物塩およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
ATE230263T1 (de) * 1996-02-29 2003-01-15 Novartis Erfind Verwalt Gmbh At1 rezeptor antagonist zur anregung von apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
CN1578772A (zh) 2005-02-09
MXPA04004013A (es) 2004-06-18
SI1442023T1 (sl) 2007-12-31
HUP0402391A3 (en) 2010-03-29
HUP0402391A2 (hu) 2005-03-29
PT1442023E (pt) 2007-09-17
CA2463146A1 (en) 2003-05-08
NO326465B1 (no) 2008-12-08
HRPK20040372B3 (en) 2006-02-28
MY129741A (en) 2007-04-30
SA02230419B1 (ar) 2007-07-31
JP2005536445A (ja) 2005-12-02
JP5124076B2 (ja) 2013-01-23
CY1107504T1 (el) 2013-03-13
UA82833C2 (uk) 2008-05-26
EA200400479A1 (ru) 2004-10-28
HRP20040372A2 (en) 2004-10-31
TW200300082A (en) 2003-05-16
UY27520A1 (es) 2003-05-30
NZ532716A (en) 2007-06-29
ES2291505T3 (es) 2008-03-01
DK1442023T3 (da) 2007-11-05
PL367477A1 (en) 2005-02-21
DE10153737A1 (de) 2003-05-28
CO5580785A2 (es) 2005-11-30
KR100929502B1 (ko) 2009-12-03
KR20050035172A (ko) 2005-04-15
DE50210719D1 (de) 2007-09-27
EP1442023B1 (de) 2007-08-15
WO2003037876A1 (de) 2003-05-08
TWI333419B (en) 2010-11-21
PE20030629A1 (es) 2003-07-14
EP1442023A1 (de) 2004-08-04
PL211462B1 (pl) 2012-05-31
MEP43608A (en) 2011-02-10
RS50879B (sr) 2010-08-31
TWI341200B (en) 2011-05-01
IL161165A (en) 2009-12-24
HK1073841A1 (en) 2005-10-21
ECSP045089A (es) 2004-06-28
TW201034664A (en) 2010-10-01
EA007596B1 (ru) 2006-12-29
YU36304A (sh) 2006-08-17
IL161165A0 (en) 2004-08-31
BR0213568A (pt) 2004-09-08
ATE370125T1 (de) 2007-09-15
AU2002338886B2 (en) 2008-04-17
CA2463146C (en) 2011-01-25
NO20041758L (no) 2004-04-29
CN100509789C (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
AR037148A1 (es) Sal sodica cristalina,procedimiento para su preparacion y su uso para la preparacion de un medicamento.
TW200509914A (en) Pharmaceutical formulation of the telmisartan sodium salt
CL2017000830A1 (es) Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino.
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
ECSP034540A (es) Monohidrato cristalino, procedimiento para su preparacion y su utilizacion para la preparacion de un medicamento
HN2012002555A (es) Activadores de guanilato ciclasa soluble
MY122755A (en) Polymorphs of telmisartan
CO6280440A2 (es) Derivados de aminobenzamida como agentes utiles para el control de parasito de animales
UY27626A1 (es) Nuevos compuestos heterocíclos, activos como inhibidores de beta-lactamasas
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
SV2004001294A (es) Derivados de acido acetico ref. lea 35699-sv
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
ES2177671T3 (es) Benzamida enterocinetica.
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
AR054361A1 (es) Uso de acido adamantil metoxidifenil propenoico para el tratamiento de enfermedades dermatologicas
AR026451A1 (es) Compuestos heterociclicos sililados
PE20010622A1 (es) Derivados de bencimidazol, sustituidos con arilsulfonamida, procedimiento para su preparacion y su empleo como medicamentos
PE20010621A1 (es) Derivados de bencimidazol sustituidos, procedimiento para su preparacion y su empleo como medicamentos
ECSP993250A (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
BR0307723A (pt) Derivados de benzimidazol substituìdos por 1-fenil-2-heteroarila, seu emprego para preparação de medicamentos bem como preparados farmacêuticos contendo esses derivados
RU2007125264A (ru) Способ лечения повреждений слизистой оболочки желудочно-кишечного тракта
UY28771A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis.
ECSP993244A (es) Cicloheptenos sustituidos, procedimiento para su preparacion y su uso como medicamento
ECSP003656A (es) Nuevos derivados del acido aminodicarboxilico con propiedades farmaceuticas

Legal Events

Date Code Title Description
FG Grant, registration